KEYTRUDA® (pembrolizumab) Clinical Trials

6 actively recruiting trials across 4 locations

▼ -1 trial since August 2026

Also known as: MK-3475

Pipeline

Phase 1: 2Phase 1/2: 4

Top Sponsors

Qurient Co., Ltd.1
Phanes Therapeutics1
Krystal Biotech, Inc.1
HC Biopharma Inc.1
Antengene Therapeutics Limited1

Indications

Cancer6
Advanced Cancer2
Gastric or Gastroesophageal Junction Adenocarcinoma1
Melanoma Stage III1
Melanoma Stage IV1

Other2 trials

A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors

Phase 1

Study of HC006 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors

Phase 1

Phoenix, Arizona1 trial

Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

Mayo Clinic

Phase 1/2

Duarte, California1 trial

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

Phase 1/2

Los Angeles, California1 trial

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

UCLA Health

Phase 1/2

Cleveland, Ohio1 trial

ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors

UH Cleveland Medical Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.